Imperial Clinical Research Services (CRS)
Imperial Clinical Research Services (CRS) is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma
Sponsor Iovance Biotherapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept (MK-7962) in Children from 1 to Less Than 18 Years of Age With PAH on Standard of Care
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Imperial Clinical Research Services (CRS)?
The 2026-10-09 snapshot links Imperial Clinical Research Services (CRS) to 2 distinct CTIS trials. Recorded services include Printing services with shipping to sites (ISF, pharmacy binders, and study documents, Recruitment & Retention. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Imperial Clinical Research Services (CRS)?
The most frequently recorded therapeutic areas are Cardiology, Dermatology, Respiratory, Solid Tumor Oncology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Imperial Clinical Research Services (CRS) conducted?
The linked trials record locations in 12 countries, including Germany, Spain, France, Netherlands, Poland. These are trial locations, not confirmed office locations or countries where Imperial Clinical Research Services (CRS) delivered services.
What can this page tell me about Imperial Clinical Research Services (CRS)'s trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Imperial Clinical Research Services (CRS). Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Imperial Clinical Research Services (CRS)